Merck & Co., Inc. (MRK) Enterprise Value (EV): $299.33B
The enterprise value (EV) for Merck & Co., Inc. (MRK) is $299.33B as of Wednesday, June 10, 2026.
MRK Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$299.33B
MRK Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Merck & Co., Inc. (MRK) | — | $299.33B |
| UnitedHealth Group Incorporated (UNH) | $368.44B | $354.42B |
| AbbVie Inc. (ABBV) | $399.54B | $470.64B |
| Amgen Inc. (AMGN) | $183.75B | $221.57B |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | $248.87B |
| Abbott Laboratories (ABT) | $154.66B | $225.43B |
| Gilead Sciences, Inc. (GILD) | $151.21B | $169.72B |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | $199.07B |
| Pfizer Inc. (PFE) | $146.36B | $207.77B |
| Danaher Corporation (DHR) | $130.25B | $175.72B |
Enterprise Value Calculation
Market Cap
$293.02B
Total Debt
$49.63B
Cash
$14.56B
Enterprise Value
$299.33B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
Merck & Co., Inc. Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for Merck & Co., Inc. (MRK)?
- The enterprise value (EV) for MRK stock is $299.33B.
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis